{
    "clinical_study": {
        "@rank": "156572", 
        "arm_group": {
            "arm_group_label": "natalizumab", 
            "arm_group_type": "Experimental", 
            "description": "Participants will be administered natalizumab 300 mg SC every 4 weeks for up to 12 treatment administrations (i.e. Day 1 through Week 44)"
        }, 
        "brief_summary": {
            "textblock": "The primary objective of this study is to evaluate the immunogenicity of natalizumab\n      (BG00002) 300 mg subcutaneous (SC) administered to subjects with relapsing multiple\n      sclerosis (RMS).  The secondary objectives of the study are to evaluate the safety of\n      natalizumab SC injections and to evaluate the efficacy of natalizumab SC injections on\n      relapses and on new magnetic resonance imaging (MRI) lesions."
        }, 
        "brief_title": "Immunogenicity and Safety Study of Natalizumab (BG00002) Administered to Participants With Relapsing Multiple Sclerosis", 
        "completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Relapsing Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Must have documented diagnosis of RMS at screening.\n\n          -  Must fall within the therapeutic indications stated in the locally approved label for\n             natalizumab.\n\n          -  Must have an EDSS score from 0 to 6.5, inclusive.\n\n        Key Exclusion Criteria:\n\n          -  Any prior use of natalizumab.\n\n          -  Positive for anti-natalizumab antibodies at screening.\n\n          -  Treatment with immunomodulatory injections (including IFN-\u03b2 and glatiramer acetate)\n             within 2 weeks prior to Screening.\n\n        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "113", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02142192", 
            "org_study_id": "101MS207", 
            "secondary_id": "2014-000917-30"
        }, 
        "intervention": {
            "arm_group_label": "natalizumab", 
            "description": "All participants will receive 2 injections delivered one after the other in order to achieve a dose of 300 mg every 4 weeks.", 
            "intervention_name": "BG00002 (natalizumab)", 
            "intervention_type": "Drug", 
            "other_name": "Tysabri"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 16, 2014", 
        "number_of_arms": "1", 
        "official_title": "A Multicenter, Open-Label Immunogenicity and Safety Study of Subcutaneous Natalizumab 300 mg Administered to Subjects With Relapsing Multiple Sclerosis", 
        "overall_contact": {
            "email": "clinicaltrials@biogenidec.com", 
            "last_name": "Biogen Idec"
        }, 
        "overall_official": {
            "affiliation": "Biogen Idec", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Denmark: Danish Health and Medicines Authority", 
                "Italy: The Italian Medicines Agency", 
                "Netherlands: Medical Ethics Review Committee (METC)", 
                "Germany: Federal Institute for Drugs and Medical Devices"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Persistent anti-natalizumab antibodies are defined as 2 positive anti-natalizumab test results separated by at least 6 weeks, with at least 1 positive test result occurring at or after the Week 24 Visit.", 
            "measure": "Proportion of subjects with persistent anti-natalizumab antibodies", 
            "safety_issue": "Yes", 
            "time_frame": "48 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02142192"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of participants with transient anti-natalizumab antibodies", 
                "safety_issue": "Yes", 
                "time_frame": "48 weeks"
            }, 
            {
                "description": "Including hypersensitivity reactions, anaphylactic reactions and other AEs occurring within 1 hour after SC natalizumab dosing.", 
                "measure": "Proportion of participants with post-injection adverse events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "48 weeks"
            }, 
            {
                "description": "This may include new or enlarging T2 lesion(s), as determined by magnetic resonance imaging (MRI).  Clinical relapse is defined as new or recurrent neurological symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the neurologist.", 
                "measure": "Proportion of participants with clinical relapse", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }, 
            {
                "description": "As determined by MRI.", 
                "measure": "Proportion of participants with gadolinium (Gd) enhancing lesion(s)", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }, 
            {
                "measure": "Proportion of Participants that experience Adverse Events and Serious Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 56 weeks"
            }
        ], 
        "source": "Biogen Idec", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biogen Idec", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}